Albert Ong

Understanding variation between kidney centres in implementation of tolvaptan in the management of autosomal dominant polycystic kidney disease: a multiple case study

Abstract Background Autosomal dominant polycystic kidney disease (ADPKD) affects an estimated 12.5 million people worldwide and 70,000 in the United Kingdom (UK). Tolvaptan is the only disease-modifying therapy available. Despite national guidelines, prescribing varies across UK...

An integrin beta-1-anchored bicaudal C1-polycystin-1 module essential for tubular morphogenesis in polycystic kidney disease

Genetic variants in the RNA-binding protein bicaudal C1 (BICC1) have been linked to very-early-onset polycystic kidney disease (PKD). This study identifies a crucial integrin-beta1 (ITGB1)-BICC1-polycystin-1 (PC1) complex that regulates F-actin organization and cell adhesion in h...